Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Jun 2019

Due to the apparent risk of adverse outcomes of disease and adverse events (AEs) associated with short-acting beta-agonists (SABA), the Global Initiative for Asthma (GINA) 2019 guideline recommends that all patients with mild asthma should receive symptom-driven or regular low-dose inhaled corticosteroid (ICS)containing controller treatment.

Advancing the treatment paradigm of idiopathic pulmonary fibrosis (IPF)

22 Jan 2018
Literature suggests that IPF is either the first or second most common interstitial lung disease (ILD) in pulmonology practice, with prevalence ranging from 17–86%. At the recent 3rd Respiratory Forum organized by Boehringer Ingelheim, Dr Felix Chua shared his insights into the importance of advancing the treatment paradigm of IPF, and the role of nintedanib (OFEV®) in its management.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 25 Jun 2019

Due to the apparent risk of adverse outcomes of disease and adverse events (AEs) associated with short-acting beta-agonists (SABA), the Global Initiative for Asthma (GINA) 2019 guideline recommends that all patients with mild asthma should receive symptom-driven or regular low-dose inhaled corticosteroid (ICS)containing controller treatment.